反应详情

温度

150 °C

To a mixture of 4-[5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-2,3-dihydro-benzofuran-2-yl]-piperidine-1-carboxylic acid isopropyl ester (41.5 mg) and N-(6-chloro-pyridazin-3-yl)-acetamide (25.7 mg) in dioxane (2 mL) a 2 M aqueous Na2CO3 solution (0.125 mL) is added. The mixture is sparged with argon for 10 min and (2-dicyclohexylphosphino-2′,6′-dimethoxy-1,1′-biphenyl)[2-(2-aminoethylphenyl)]palladium(11) chloride*methyl-t-butylether complex (CAS-number.: 1028206-58-7; 8 mg) is added. The resulting mixture is stirred for 1 h at 150° C. After cooling to room temperature, the mixture is filtered over basic alumina and eluted with N,N-dimethylformamide/MeOH (9:1; 2 mL). The solvent is evaporated and the residue is purified by preparative HPLC (eluent water (+0.1% NH3)/MeOH) to yield the desired product. HPLC (method 13): tR=0.26 min; Mass spectrum (ESI+): m/z=425 [M+H]+.

1. additionis added
2. customThe mixture is sparged with argon for 10 min
3. addition(2-dicyclohexylphosphino-2′,6′-dimethoxy-1,1′-biphenyl)[2-(2-aminoethylphenyl)]palladium(11) chloride*methyl-t-butylether complex (CAS-number.: 1028206-58-7; 8 mg) is added
4. temperatureAfter cooling to room temperature
5. filtrationthe mixture is filtered over basic alumina
6. washeluted with N,N-dimethylformamide/MeOH (9:1; 2 mL)
7. customThe solvent is evaporated
8. customthe residue is purified by preparative HPLC (eluent water (+0.1% NH3)/MeOH)